106 related articles for article (PubMed ID: 2455140)
1. A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine.
Poulter N; Thompson AV; Sever PS
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S53-6. PubMed ID: 2455140
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
Svetkey LP; Weinberger MH; Gavras H; Gavras I; Brown TS; Deterding J; Klotman PE
J Clin Hypertens; 1987 Dec; 3(4):579-88. PubMed ID: 3330988
[TBL] [Abstract][Full Text] [Related]
3. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
[TBL] [Abstract][Full Text] [Related]
4. Comparison of nifedipine (retard formulation) and mefruside in the treatment of mild to moderate hypertension--a prospective randomized double-blind crossover study in general practice.
Douglas-Jones AP; Mitchell AD
Postgrad Med J; 1984 Aug; 60(706):529-32. PubMed ID: 6382224
[TBL] [Abstract][Full Text] [Related]
5. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.
Witchitz S; Serradimigni A
J Hum Hypertens; 1989 Jun; 3 Suppl 1():29-33. PubMed ID: 2550643
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O
Cardiologia; 1996 Jul; 41(7):635-43. PubMed ID: 8831181
[TBL] [Abstract][Full Text] [Related]
9. Nicardipine versus nifedipine: multicentre controlled trial in essential hypertension.
Rumboldt Z; Stojanova D; Drinovec J; Marinković M; Nesović M; Srbinovski M; Bagatin J; Nikodijević B; Stalc A
Int J Clin Pharmacol Res; 1988; 8(6):393-400. PubMed ID: 3075601
[TBL] [Abstract][Full Text] [Related]
10. [Controlled study on the treatment of hypertension with verapamil in retard form].
Belz GG; Spies G
Z Kardiol; 1985 Aug; 74(8):453-9. PubMed ID: 3901562
[TBL] [Abstract][Full Text] [Related]
11. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen W; Wilson T
Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
[TBL] [Abstract][Full Text] [Related]
12. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
13. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
Harder S; Rietbrock S; Thürmann P
Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
[TBL] [Abstract][Full Text] [Related]
15. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension.
Kirsten R; Heller A; Heintz B; Nelson K
J Hum Hypertens; 1990 Aug; 4(4):461-4. PubMed ID: 2258894
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation by practicing physicians of the antihypertensive efficacy of debrisoquin, methyldopa and propranolol].
Avigdor L; Waeber B; Brunner HR
Schweiz Med Wochenschr; 1983 Mar; 113(9):331-8. PubMed ID: 6342133
[TBL] [Abstract][Full Text] [Related]
17. Effect of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension.
Ogilvie RI
Can Med Assoc J; 1985 May; 132(10):1137-41. PubMed ID: 3995432
[TBL] [Abstract][Full Text] [Related]
18. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of amlodipine and the nifedipine retard preparation in the treatment of arterial hypertension].
Pivac N; Dobovisek J; Bagatin J; Gros Furek V; Rumboldt Z; Janezić A; Kveder R; Sjerobabski V; Simunić M; Sardelić S
Lijec Vjesn; 1993; 115(11-12):356-9. PubMed ID: 8176999
[TBL] [Abstract][Full Text] [Related]
20. Slow-release metoprolol and nifedipine in essential hypertension: 24 hour noninvasive ambulatory blood pressure monitoring.
Lattuada S; Antivalle M; Rindi M; Montanari M; Alberti D; Libretti A
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S99-101. PubMed ID: 2455155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
